- Home
- RQI vs TARS Comparison
RQI vs TARS Comparison
Compare RQI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- TARS
- Stock Information
- Founded
- RQI 2002
- TARS 2016
- Country
- RQI United States
- TARS United States
- Employees
- RQI N/A
- TARS N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- TARS Medicinal Chemicals and Botanical Products
- Sector
- RQI Finance
- TARS Health Care
- Exchange
- RQI Nasdaq
- TARS Nasdaq
- Market Cap
- RQI 1.7B
- TARS 1.7B
- IPO Year
- RQI N/A
- TARS 2020
- Fundamental
- Price
- RQI $12.16
- TARS $54.21
- Analyst Decision
- RQI
- TARS Strong Buy
- Analyst Count
- RQI 0
- TARS 7
- Target Price
- RQI N/A
- TARS $67.14
- AVG Volume (30 Days)
- RQI 432.6K
- TARS 678.3K
- Earning Date
- RQI 01-01-0001
- TARS 08-06-2025
- Dividend Yield
- RQI 8.20%
- TARS N/A
- EPS Growth
- RQI N/A
- TARS N/A
- EPS
- RQI N/A
- TARS N/A
- Revenue
- RQI N/A
- TARS $295,521,000.00
- Revenue This Year
- RQI N/A
- TARS $122.94
- Revenue Next Year
- RQI N/A
- TARS $44.14
- P/E Ratio
- RQI N/A
- TARS N/A
- Revenue Growth
- RQI N/A
- TARS 254.45
- 52 Week Low
- RQI $9.17
- TARS $24.95
- 52 Week High
- RQI $12.64
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- RQI 40.70
- TARS 78.63
- Support Level
- RQI $12.08
- TARS $40.55
- Resistance Level
- RQI $12.42
- TARS $42.11
- Average True Range (ATR)
- RQI 0.16
- TARS 2.14
- MACD
- RQI -0.03
- TARS 1.38
- Stochastic Oscillator
- RQI 23.81
- TARS 94.81
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.